National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting

American Journal of Hematology

Volumn 89, Issue 6, 2014, Pages 621-625

  Soucie, J Michael ^a   Miller, Connie H ^a   Kelly, Fiona M ^a   Aschman, Diane ^b   Dimichele, Donna ^c   Konkle, Barbara A ^d   Kulkarni, Roshni ^e   Monahan, Paul E ^f  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b American Thrombosis and Hemostasis Network   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d PUGET SOUND BLOOD CENTER   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE SURVEILLANCE; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH SURVEY; HEMOPHILIA; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SCREENING; UNITED KINGDOM; UNITED STATES;

AUTOANTIBODIES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); EPIDEMIOLOGICAL MONITORING; HEMOPHILIA A; HUMANS; UNITED STATES;

EID: 84900867354     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23704     Document Type: Article

References (15)

1. European Medicines Agency. Report of expert meeting on factor VIII products and inhibitor development 28 February 2006-2 March 2006. European Medicines Agency; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500015512.pdf.
2. Hay CRM, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Hemophilia Centre Doctors Organisation. Br J Haematol 2006;133:591-605.
3. Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011;117:6367-6370.
4. Collins PW, Chalmers E., Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital hemophilia A (4th edition). Br J Haematol 2013;160:153-170.
5. Björkman S, Oh M, Spotts G, Schroth P, et al. Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight. Blood 2012;119:612-618.
6. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:c inhibitors: Improved specificity and reliability. Thromb Haemost 1995;73:247-251.
7. Giles AR, Verbruggen B, Rivard GE, et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the hemophilia A population of Canada. Thromb Haemost 1998;79:872-875.
8. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. JAMA 1999;281:824-829.
9. Soucie JM, McAlister S, McClellan A, et al. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010;38: S475-S481.
10. Soucie JM, Miller CH, Kelly FM, et al. A study of prospective surveillance for inhibitors among persons with hemophilia in the United States. Hemophilia 2014; 20:230-237; doi:10.1111/hae.12302.
11. Miller CH, Benson J, Ellingsen D, et al. F8 and F9 mutations in US hemophilia patients: correlation with history of inhibitor and race/ethnicity. Hemophilia 2011;18:375-382.
12. DiMichele DM. Immune tolerance in hemophilia: the long journey to the fork in the road. Brit J Haematol 2012;159:123-134.
13. Peerschke EIB, Castellone DD, Ledford-Kraemer M, et al. Laboratory assessment of factor VIII inhibitor titer. Am J Clin Pathol 2009;131:552-558.
14. Miller CH, Platt SJ, Rice AS, et al. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012;10:1055-1061.
15. Miller CH, Rice AS, Boylan B, et al. Comparison of clot-based, chromogenic, and fluorescence assays for measurement of factor VIII inhibitors in the U.S. Hemophilia Inhibitor Research Study (HIRS). J Thromb Haemost 2013:11;1300-1309.